[go: up one dir, main page]

HUE045098T2 - A telomerázinhibitor imetelstat alkalmazása mielofibrózis kezelésére - Google Patents

A telomerázinhibitor imetelstat alkalmazása mielofibrózis kezelésére

Info

Publication number
HUE045098T2
HUE045098T2 HUE13861008A HUE13861008A HUE045098T2 HU E045098 T2 HUE045098 T2 HU E045098T2 HU E13861008 A HUE13861008 A HU E13861008A HU E13861008 A HUE13861008 A HU E13861008A HU E045098 T2 HUE045098 T2 HU E045098T2
Authority
HU
Hungary
Prior art keywords
mimelstat
myelofibrosis
treatment
telomerase inhibitor
telomerase
Prior art date
Application number
HUE13861008A
Other languages
English (en)
Inventor
Monic Stuart
Stephen Kelsey
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of HUE045098T2 publication Critical patent/HUE045098T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
HUE13861008A 2012-12-07 2013-11-15 A telomerázinhibitor imetelstat alkalmazása mielofibrózis kezelésére HUE045098T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05

Publications (1)

Publication Number Publication Date
HUE045098T2 true HUE045098T2 (hu) 2019-12-30

Family

ID=50883867

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE13861008A HUE045098T2 (hu) 2012-12-07 2013-11-15 A telomerázinhibitor imetelstat alkalmazása mielofibrózis kezelésére
HUE18196690A HUE049858T2 (hu) 2012-12-07 2013-11-15 A telomerázgátló imetelstat alkalmazása mielodiszpláziás szindróma kezelésére
HUE19187756A HUE066402T2 (hu) 2012-12-07 2013-11-15 A telomerázinhibitor imetelstat mieloproliferatív rendellenességek és mieloproliferatív neopláziák kezelésére

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE18196690A HUE049858T2 (hu) 2012-12-07 2013-11-15 A telomerázgátló imetelstat alkalmazása mielodiszpláziás szindróma kezelésére
HUE19187756A HUE066402T2 (hu) 2012-12-07 2013-11-15 A telomerázinhibitor imetelstat mieloproliferatív rendellenességek és mieloproliferatív neopláziák kezelésére

Country Status (35)

Country Link
EP (3) EP3646876B1 (hu)
JP (5) JP6433911B2 (hu)
KR (3) KR102294819B1 (hu)
CN (2) CN111617252A (hu)
AP (1) AP2015008504A0 (hu)
AU (4) AU2013356533B2 (hu)
BR (1) BR112015013260A2 (hu)
CA (2) CA3188494A1 (hu)
CL (2) CL2015001530A1 (hu)
CY (2) CY1122169T1 (hu)
DK (3) DK3646876T3 (hu)
EA (1) EA032973B1 (hu)
ES (3) ES2982897T3 (hu)
FI (1) FI3646876T3 (hu)
HK (2) HK1210940A1 (hu)
HR (3) HRP20240624T1 (hu)
HU (3) HUE045098T2 (hu)
IL (3) IL317233A (hu)
LT (3) LT3456333T (hu)
MA (2) MA38193B1 (hu)
ME (1) ME03538B (hu)
MX (3) MX372753B (hu)
MY (1) MY180634A (hu)
NZ (1) NZ708920A (hu)
PH (2) PH12019501008A1 (hu)
PL (3) PL3456333T3 (hu)
PT (3) PT3456333T (hu)
RS (2) RS60401B1 (hu)
SG (3) SG11201504383TA (hu)
SI (3) SI3646876T1 (hu)
SM (2) SMT202000328T1 (hu)
TN (1) TN2015000249A1 (hu)
UA (3) UA117116C2 (hu)
WO (1) WO2014088785A1 (hu)
ZA (2) ZA201504124B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778711B1 (en) 2004-07-02 2017-08-16 Geron Corporation Synthesis of protected 3'-amino nucleoside monomers
CR20190343A (es) 2013-08-07 2019-10-02 Incyte Corp FORMAS DE DOSIFICACIÓN DE LIBERACIÓN PROLONGADA PARA UN INHIBIDOR DE JAK 1 (Divisional de Exp: 2016-0102)
DK3065828T3 (en) * 2013-11-06 2019-04-15 Mayo Found Medical Education & Res METHODS AND MATERIALS FOR TREATING HEMATOLOGICAL MALIGNITIES
CN107429247B (zh) 2015-04-23 2021-08-13 美国杰龙生物医药公司 使用多价阳离子盐组合物制备多核苷酸的方法
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JP7316261B2 (ja) 2017-07-28 2023-07-27 ジェロン・コーポレーション 骨髄異形成症候群の治療方法
JP2021523220A (ja) * 2018-04-30 2021-09-02 カルトス セラピューティクス，インコーポレイテッド がんの治療方法
CN112770783B (zh) * 2018-07-31 2025-02-25 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
AU2019389005B2 (en) 2018-11-29 2024-06-20 Geron Corporation Methods of treating myelodysplastic syndrome
MX2022005354A (es) * 2019-11-04 2022-10-21 Geron Corp Uso de un inhibidor de la cinasa janus y un inhibidor de la telomerasa para el tratamiento de neoplasias mieloproliferativas.
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置
WO2024259369A1 (en) * 2023-06-14 2024-12-19 Rarecells Inc. Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
CA2274586A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2515000A1 (en) * 2003-01-31 2004-08-19 Jessie L.-S. Au Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
PL1667522T3 (pl) 2003-09-09 2018-06-29 Geron Corporation Zmodyfikowane oligonukleotydy do hamowania telomerazy
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
EP1778711B1 (en) 2004-07-02 2017-08-16 Geron Corporation Synthesis of protected 3'-amino nucleoside monomers
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
PL2898887T3 (pl) 2006-10-30 2019-05-31 Geron Corp Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
EP3456333B8 (en) 2020-05-13
EP2928477A4 (en) 2016-09-21
MX2020003276A (es) 2020-07-20
AP2015008504A0 (en) 2015-06-30
KR20150091130A (ko) 2015-08-07
MA38193B1 (fr) 2018-12-31
PH12015501282A1 (en) 2015-08-24
AU2024203138A1 (en) 2024-07-25
AU2013356533A1 (en) 2014-06-12
PH12019501008A1 (en) 2022-11-14
AU2020267142B2 (en) 2024-05-16
WO2014088785A8 (en) 2015-07-16
DK3646876T3 (da) 2024-05-06
ZA202108991B (en) 2023-05-31
JP7288098B2 (ja) 2023-06-06
RS60401B1 (sr) 2020-07-31
UA126015C2 (uk) 2022-08-03
CN111617252A (zh) 2020-09-04
EP3456333A1 (en) 2019-03-20
JP2022179684A (ja) 2022-12-02
PL3646876T3 (pl) 2024-07-22
JP2022050537A (ja) 2022-03-30
ES2982897T3 (es) 2024-10-18
MX2015007169A (es) 2016-03-31
HUE049858T2 (hu) 2020-11-30
CN104936602A (zh) 2015-09-23
HRP20191784T1 (hr) 2019-12-27
UA117116C2 (uk) 2018-06-25
CA3188494A1 (en) 2014-06-12
EP3646876B1 (en) 2024-02-14
CL2015001530A1 (es) 2016-03-28
NZ748134A (en) 2020-10-30
CA2892907C (en) 2023-03-21
HRP20200993T1 (hr) 2020-11-27
CL2017002156A1 (es) 2018-05-04
TN2015000249A1 (en) 2016-10-03
IL280144A (en) 2021-03-01
CN104936602B (zh) 2020-07-17
MX372753B (es) 2025-03-05
FI3646876T3 (fi) 2024-05-14
MA38193A1 (fr) 2017-12-29
PT3646876T (pt) 2024-05-15
RS59363B1 (sr) 2019-11-29
AU2013356533B2 (en) 2018-09-27
BR112015013260A2 (pt) 2018-02-06
JP2020041001A (ja) 2020-03-19
CY1122169T1 (el) 2020-11-25
JP2018035196A (ja) 2018-03-08
IL317233A (en) 2025-01-01
SMT201900567T1 (it) 2019-11-13
ZA201504124B (en) 2017-05-31
EA032973B1 (ru) 2019-08-30
NZ708920A (en) 2020-08-28
MX2022015437A (es) 2023-01-11
MY180634A (en) 2020-12-03
SI3456333T1 (sl) 2020-10-30
LT3456333T (lt) 2020-06-25
LT3646876T (lt) 2024-05-10
KR102294819B1 (ko) 2021-09-01
IL239266A0 (en) 2015-07-30
CA2892907A1 (en) 2014-06-12
HK1212226A1 (en) 2016-06-10
JP2016504307A (ja) 2016-02-12
AU2018282364A1 (en) 2019-05-23
SI3646876T1 (sl) 2024-07-31
IL280144B1 (en) 2025-01-01
JP6998191B2 (ja) 2022-02-04
PT3456333T (pt) 2020-06-01
DK2928477T3 (da) 2019-10-07
EP3646876A1 (en) 2020-05-06
SMT202000328T1 (it) 2020-07-08
UA128370C2 (uk) 2024-06-26
ES2789176T3 (es) 2020-10-26
AU2020267142A1 (en) 2020-12-03
KR102662590B1 (ko) 2024-05-03
HK1210940A1 (en) 2016-05-13
HUE066402T2 (hu) 2024-07-28
JP6433911B2 (ja) 2018-12-05
PL2928477T3 (pl) 2020-03-31
MA45504B1 (fr) 2021-10-29
SI2928477T1 (sl) 2019-11-29
IL239266B (en) 2019-11-28
MA45504A1 (fr) 2020-05-29
WO2014088785A1 (en) 2014-06-12
HRP20240624T1 (hr) 2024-08-02
KR20230028590A (ko) 2023-02-28
ME03538B (me) 2020-07-20
EA201590878A1 (ru) 2016-04-29
LT2928477T (lt) 2019-10-10
EP2928477B1 (en) 2019-07-24
EP3456333B1 (en) 2020-04-01
SG10202103341SA (en) 2021-05-28
ES2744790T3 (es) 2020-02-26
KR20210107906A (ko) 2021-09-01
PT2928477T (pt) 2019-10-25
CY1123206T1 (el) 2021-10-29
SG11201504383TA (en) 2015-07-30
DK3456333T3 (da) 2020-05-18
PL3456333T3 (pl) 2020-09-21
PH12015501282B1 (en) 2015-08-24
EP2928477A1 (en) 2015-10-14
AU2020267142C1 (en) 2024-08-08
SG10201802926XA (en) 2018-05-30

Similar Documents

Publication Publication Date Title
HUE045098T2 (hu) A telomerázinhibitor imetelstat alkalmazása mielofibrózis kezelésére
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
HUE036259T2 (hu) Inhibitor vegyületek
DK2684610T4 (da) Bruser
EP2857724A4 (en) ROTARY VALVE
EP2902029A4 (en) RET INHIBITOR
SG11201501173SA (en) PI3Kδ INHIBITOR
EP2857723A4 (en) ROTARY VALVE
HK1211210A1 (zh) 治療多發性硬化症的組合療法
EP2968204A4 (en) TREATMENT WITH A PHOSPHODIESTERASE HEMMER
DK2692448T3 (da) Brusehoved
ZA201406082B (en) Use of ccr3-inhibitors
HUE054053T2 (hu) Diagnosztikai markerek sejtproliferatív rendellenseségek telomerázgátlóval történõ kezeléséhez
DK2827998T3 (da) Brusehoved
EP2933248A4 (en) NOVEL RENIN INHIBITOR
FR2997173B1 (fr) Convertisseur thermo-electrique
EP2940852A4 (en) CONVERTER
HK1219273A1 (zh) 磷酸二酯酶 型的新型抑制劑化合物
ITRM20120473A1 (it) Use of glycerophosphoinositols for the treatment of septic shock
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
DK2704705T3 (da) Anvendelse af bethanechol til behandling af xerostomi
UA23851S (uk) Профіль рознімний
ES1078577Y (es) Ducha de mano
GB201318433D0 (en) Candidate for the treatment of epilepsy
UA25448S (uk) Застібка